Tarsons Products Ltd
NSE:TARSONS
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
379.85
553.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Tarsons Products Ltd
You don't have any saved screeners yet
Ladies and gentlemen, good day, and welcome to Tarsons Products Limited Q1 FY '24 Earnings Conference Call hosted by AMBIT Capital. And there will be an opportunity for you to ask questions after the presentation concludes. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Karan Khanna from AMBIT Capital. Thank you, and over to you, sir.
Thank you, operator, and good morning, everyone. On behalf of AMBIT Capital, I welcome you all to the 1Q FY '24 Earnings Call for Tarsons Products. From the management team today, we have Mr. Rohan Sehgal, Full Time Director; and Mr. Santosh Agarwal, Chief Financial Officer. I will now hand over the call to the management team for the opening remarks, post which we can start the Q&A session. Thank you, and over to you, Rohan.
Good afternoon, and a very warm welcome to everyone present on the Q1 FY '24 Earnings Conference Call for Tarsons Products Limited. Along with me today, I'm joined by Mr. Santosh Agarwal, the Chief Financial Officer and the Company Secretary; and SGA, our Investor Relations advisers.
We have uploaded our quarterly investor presentation on the stock exchanges and company's website. I hope all of you had an opportunity to go through the same. Let me begin by offering some background information about the industry.
Currently, the life science sector is experiencing a slowdown leading to a notable reduction in demand for plastic [indiscernible] products. Growth in the international and domestic market. As a result of this deceleration and weakened demand, the overall industry has contracted, shrinking by over 15%. However, our revenues for this quarter have seen a 9% decrease. It is important to note that while our revenue of ours have declined by 9%, we have been exceeding industry trends and enhancing our market position compared to our peers.
Another contributing factor to the decline in this -- in the revenue is the high level of inventory, which is there in the distribution channel. Looking ahead, we hold an optimistic view regarding an industry resurgence and the normalization of channel inventory levels, which should pave the way for the revising inflow.
Let me speak about the inorganic growth opportunity. Our strategic vision is firmly succeeded on a significant growth potential that the export market holds for us. To harness this potential, our approach involves the acquisition of a brand or a distribution channel, a move aimed at establishing a strong presence in the overseas market. The basis of our strategy involves an inorganic opportunity that foster the strengthening of our channel and distribution partnerships, proceed primarily results around the acquisition of brands, channel partners, large distributors, allowing us to fortify our network and extend our market increments.
Our strategic scope extends beyond channel enhancement in focusing a comprehensive exploration of various acquisition prospects. This comprehensive approach underscores our commitment to diversification as we seek opportunities that align with our strategic objectives and resonate with our growth aspirations.
While we embark on this strategy of inorganic opportunities, we recognize that there will be associated costs. These costs are an integral part of this process, involving the investments required to actualize our expansion objectives and enhance the diverse range of our business proceeds. We are in active process of evaluating such acquisitions, a strategic move aimed at bolstering our global footprint and expediting our journey towards accelerated growth.
On the EBITDA front, the reported EBITDA margin for Q1 FY '24 was at 24% during the quarter. This decline was due to the lower absorption of fixed expenses due to decline in revenues affecting margins. We have also allocated increased resources towards new product development and bolstering our marketing efforts for our plan to manufacture new products by expanding our capacities. While this proactive approach lays the groundwork for future growth, it has momentum contributed to higher operational costs.
In line with our growth strategy, we are gearing up for capacity expansions and establishment of new manufacturing units. This forward-looking investment associates increased spending in the short term, which will generate higher revenue going forward. Our EBITDA was also impacted on account of a onetime expense of INR 2.8 crores, which was incurred for the due diligence charges associated with the potential inorganic opportunity. Regrettably, this opportunity did not fructify due to a valuation mismatch. After adjustments for the impact of this onetime item, our adjusted EBITDA is INR 24.1 crores with margins of 38.5%.
On the CapEx front, first, on the Partial facility, Marchla is introducing cell culture and increasing capacity in existing products. Construction has been completed, and our first triannual is completely ready. We are, however, awaiting certain machines that are already in front it. We anticipate that the first round of production will begin in Q3 FY '24.
Furthermore, cell culture and other products are expected to begin commencing production in Q4 FY '24 in Q1 FY '25 in a phased manner. The second plant, which is the AMPA plant, we are building a radiation plant and have signed a memorandum of understanding that the both of radiation and isotope technology grid to do so. This will reduce our dependency on a sole vendor in our open region. We are also building a central warehouse operation, which will -- which is currently under construction. We are shifting our bioprocess manufacturing from a rented facility to this facility in the coming months, which will have higher operational efficiencies going forward.
Before handing over the call to Santosh, I'd like to state that in the short term, [indiscernible] difficult due to the macro environment, which was clearly impacted most of the larger players in the industry. However, we are confident in our strategies to take portions at high levels. with our expansion in new products as well as acquisition opportunities, we have a for a bright future.
With this, I would like to hand over the call to Mr. Santosh Agarwal, CFO of Tarsons, for his comments on the financial highlights.
Good morning, everyone, and a very warm welcome. Let me take you through the financial highlights for Q1 FY '24. On the revenue front, revenue from operations for Q1 FY '24 should add INR 53 crores as compared to INR 69 crores in Q1 FY '23, lower by 9% on a Y-o-Y basis. However, the overall industry and other organized peers have seen a dip of more than 15%.
For Q1 FY '24, [indiscernible] stood at INR 17 crores and domestic earnings stood at INR 45 crores. For Q1 FY '24, export sales contributed around 27% and domestic sales contributed around 173%. At a gross profit level, our gross profit for Q1 FY '24 is stood at INR 47 crores as compared to INR 54 crores in Q1 FY '23. Our GP margin for Q1 FY '24 stood at 75.1%.
On EBITDA term, our adjusted EBITDA for Q1 FY '24 stood at INR 24.1 crores with adjusted EBITDA margin of 38.5%. This has been adjusted for INR 2.8 crores one-off expenses on account of [indiscernible] charges for a potential revenue opportunity. Our reported EBITDA for Q1 FY '24 stood at INR 31.3 crores as INR 31.1 crores in Q1 FY '23. Reported EBITDA margin for Q1 FY '24 stood at 34%.
At the current level, profit after tax for Q1 FY '24 was INR 9.3 crores with PAT margin of 15.3%. With this, I would like to open the floor for Q&A.
We will now begin the question-and-answer session. [Operator Instructions] Our first question is from the line of Omkar Kamtekar from Bonanza Portfolio.
First question is there has been increase in the employee expenses in this moment in line with...
Mr. Omkar, may we request you to use your handset, please?
Okay. Is it better now?
Yes, sir, please go ahead.
Okay. So firstly, there is an increase in the employee expense. So this is the normal annual increase in the employee expense or there has been some additional employees being employed for the new plant and et cetera? Is it the clarification on that?
So the increase in the employees is majorly the annual increase in the employee year-on-year compensation increased for approximately 650-odd employees. However, there have been some new hires and very little contribution has come in the first quarter because many of them have joined over the last 8 to 10 weeks.
So moving forward, we have seen some increase in employee expenses for the new hires, which would show completely in the third quarter. There will be 1 month, which is the third month of the first quarter, which must have seen certain new hire employee expenses.
Okay. So then we can expect the employee expense to increase a bit further in the upcoming quarters?
Certainly. But these employees are being hired for the new facilities, were for more product lines, which for us is expected to increase revenues. So overall, in the long term, I don't see the employee percentage to the revenue moving drastically from where it is today. It should be in the same range.
Got it. Got it. And sir, with respect to the acquisition, the one that was not able to certify. So could you -- is it possible for you to give us a range of what was the proposed mismatch in the value? So like what was the deal value that you were proposing and what was the contracted demand wouldn't that be disclosable?
Yes. So I think we were one of the front runners in the acquisition and the valuation reported by us was among the top 2, 3 valuations. However, based on the final due diligence and a lot of other activities, as you see revenues are dropping, worldwide revenues are dropping for a lot of companies because of reduced demand. So the person who actually acquired the company and won the bid, did not re-rate the number which was originally given. We entered and related the number because earnings and revenue has fallen for the proposed acquisition. So the variance was approximately 20% to 25%. That's all I could mention.
Okay. So you will not be able to give the number?
Sir, we have signed a nondisclosure agreement with the potential target, so we cannot disclose the number.
Fine. And just final follow-up on that. Are there any other acquisitions in line with these that are identified for inorganic acquisition?
So we have certain agencies who are working for us, are looking at potential targets. And as and when new clients with a good target, we will move ahead to the next stage to next year further. But this is an active work which is going on as continuously at the company.
Our next question is from the line of Jesse Walia from Clock Wine Capital.
So how did you see demand trends during the first quarter across various segments? And how are you seeing those trends incremental?
So the demand in the first quarter has been relatively lower for the consumables segment as compared to the other segments. Understandably so because there is a large overstock and an overhang from COVID because 95% of the plastic yields during COVID was consumables. So we see a lot of demand reduction in the consumable space, the other sectors, which is reusable plastics and the instrumentation sector is relatively lower affected as compared to the consumer center.
Got it. And sir, can you also talk about the demand across segments like diagnostics, pharma, research?
So at this point of time, as I said in our earlier calls, I think the Diagnostic and the Research and Pharma segment relatively remains a lower requirement for plastics as impact to previous quarters and forward as well as the pre-COVID quarters, which led up to COVID. The biotech in the CRO segment continue to perform very, very well.
And the other sectors, specifically in India, continue to underperform. I still feel that we've always if you look at our revenue concentration of 73% and 27%, I still feel that the pressure in the Asians are confident is much higher than the European and American up continent. Of course, our stronger position in Asia will be able to generate more revenues. But Asia at this point of time seems to be having a tougher time repopulating as compared to Europe and U.S., although the entire world is going through a very, very sluggish phase in the plastic labor market.
And across these various segments, are you seeing signs of recovery for any of the segments or probably all segments are showing similar trends?
See, an issue is that there is these inventory levels at the customer and as well compared to the distributor and certain large customers have also panic order so much of inventory, which we are slowly moving out and slowly clearing out. So recovery levels were there, which was there in the Q4 levels, we did much better compared to the previous 3 quarters, but that had a lot of effects of customers only to complete their targets, the salespeople wanted to complete their targets distributors wanting to complete their targets as well as a strong push tarps from our side as well in the domestic market. But recovery levels are there, but they are very slow. I do not see a complete recovery in this quarter as we have -- as we're talking in Q2. But recovery in the domestic and international market is not as strong as what we had expected for Q2.
Got it. And sir, on the competition front, are you seeing pricing pressure in the market? Or your view on that front remain the same as in the previous quarters?
I think [indiscernible] your question, please. Could you repeat it?
So on the competition front, are you seeing incremental pricing pressure in the market because there's a lot of capacity which are [indiscernible]. Sorry, on the competition front, are you seeing incremental pressure on pricing because launch capacity has come in, particularly in China. Is that leading to lower realizations in some of the segments?
So there is -- I think it's not only China, but it's globally that there has been a lot of capacity. So globally, the market has become competitive. We don't see a lot of lower realizations, as you can see from the bigger margins within pretty much impact to where it was.
But yes, there is a global competitive pressure, which it seems slightly temporary. And there was an involvement of a lot of new players over the last 2 to 3 years. But we see players retracting back as well as the industry does not cause the kind of liquid asset posted going forward for the new players.
Got it, sir. Sir, my last question, sir. Sir, how much of cell culture products are exported by Chinese companies? And what is it as a percentage of global production of cell culture products?
I won't have identical numbers for you at this point of time. But I think China would export close to $70 million to $80 million in of cell-culture products, this purely cell culture consumables out to the rest of the world. And I don't know what percentage that would be of the total volume, but it will be a very insignificant or small percentage.
Cell culture still primary dominated by the [indiscernible] in the U.S.
[Operator Instructions] Our next question is from the line of Jaiveer Shekhawat from AMBIT Capital.
My first question is in relation to how you think about your acquisition strategy. Given this quarter, you only spent about 5% of your top line on the ease of an acquisition which will materialize. And how do you think about, say, further acquisitions down the line? Would you be looking to those sales and that substantial amount of the acquisitions?
Jaiveer, could you please repeat the question? Your voice is not coming in properly.
Can you hear me now?
Yes, yes.
Yes. I was trying to understand about your acquisition strategy given this quarter, you almost spent 5% of your pure top line due to the reasons do reasons of an acquisition which wouldn't materialize. So your thoughts there?
Right. So see, the thing is we spent approximately INR 2.8 crores on the acquisition due diligence, which would have been no different had the acquisition on Unfortunately, the times are very volatile at this point of time as you see our revenues have not shown up. And you can imagine certain companies where an acquisition process is not an overnight process. It is about 6 to 8 months. And by the time you sign an agreement with the party to move ahead and get an offer embed, which gets accepted and start the due diligence and complete the due diligence is approximately 4 to 6 months. And in 4 to 6 months in this volatile industry, we've seen numbers totally disintegrate.
And what was shown to us and what actually was the due diligence number based on 6 months of de-growing revenue, things are very different. So we thought prudently that at that point of time, we had to discount the number which was traditionally given because of the lower numbers and the lower earnings. However, some of the competitors who did in decided to stick with the original number and they won the bid. So we would stick to this strategy moving forward as well. I think this is a big time because the industry is slowing down and we could come across some good companies at very, very attractive valuations to acquire. But in this process, we might end up spending some one-off expenses, which I think would be worth it if we is able to find the right company.
Related to this is in terms of the export revenue. So what we have seen is when you compare Tarsons' export revenue to the overall market potential, it's quite negligible. And if I see your export revenue drive has been largely flattish or declining over the last 2.5, 3 years despite the wide range of products that you have.
So could you highlight on the challenges that you are facing on this front? And why are you not able to increase your wallet share with large multimillion dollar enterprises that you deal business with despite the side that your unlisted peers, they have found avenues to multiply that scale of business?
Right. So if you look at our international revenue, it constantly grew, right, up to FY '22. We saw a slight decline in FY '23 from FY '22. So that was the first year of international decline what we saw in the international markets. Apart from that, from 2010 to 2022, we've constantly grown.
Now at this point of time, we have strong relationships with large factor companies and other large importers all over the world. But it is -- as I explained, it's a time where people have large amounts of inventory and unsold inventory -- and it is not a time when they would like to bring in new inventory of bringing new relationships with our existing relationships, bringing new product categories. So we will wait for the market to actually stabilize and inventories, some channels started using before we start looking at newer opportunities.
At this point of time, as I do not have any numbers on 1 ministered peers, it's not available. We do not see any growth or even flat revenue of any of the unlisted players in the international market, it saw a declining trend from '23 onwards. Pre-'23, I do believe [indiscernible]. But the story post '22 has been very similar of the industry of what our story is. There is no difference as per our understanding.
And lastly, my question is regarding the commentary that you have been giving around the outlook. So if I just go a quarter back in your fourth quarter earnings call as well as in the investor presentation you were highlighting about the demand pickup and the early times of the industry. And even if I grow sales fourth quarter and second quarter of the last year, you're also leading to the fact that your conventional business was growing. It is actual forward business, possibly in 23, 25 percentage on a year-on-year basis.
Now this quarter, we have seen -- I mean, despite no COVID-related revenues in the base, I mean your convention base also declined. So I'm just trying to resolve this onetime and why is it that the outlook for the industry is changing so in a very volatile fashion, especially on a quarter to all basis? And second is in terms of your confidence to really ramp up your revenue post your pencil commissioning? Or would it be possible that you might end the year on a flattish node itself?
Sure so if you see, we ended FY '22 with our best performance ever in the history of the company. And FY '22 was March '22. So those March '22, we had a large influx of orders, which we could not suffice. And a lot of that over-ordering which was there on back order, what we would call was suffice to the next 2 months post March 22, which we did not have enough capacities to be given.
So while we did not have any new ordering throughout April, May, June of last year. Our new orders this year are much better than our new orders last year, but we do not have the backing of a large forward behind us this year. And hence, lower revenues, the picture looks very different. The store looks very different because it shows more revenue as compared to last year, but we had -- we were coming off a quarter, which was the best ever quarter in the history of the company and a best set a year in the ministry of the company, which we are not coming off this year.
So primarily, that is the main difference between last quarter and this year. And look at orders received or fresh orders received, I think the first 5.5 months as we speak today on 14 of August, the fresh orders received domestically and internationally are much stronger than last year's fresh orders received.
Understood. So in terms of your outlook for the rest of the year, do you believe you -- are you likely to engage on a flattish note? Or would you be able to increase your revenues toward the punishment?
So at this point of time, we still believe we can increase our revenues compared to last year, but we will move ahead and see how the industry the act in performing and performed over the next 3 quarters. As you see, the industry trends have been very, very volatile. We did extremely well in the previous quarter, which was Q4, and then Q1 has again come down. But it's very similar to whatever available data has done in the industry from global peers. If you look at the Q1 numbers, it was much stronger and the Q2 numbers have declined because most of the international companies work on Jan to December. So the Q1 was stronger and a recovery and then Q2 then came down.
Our next question is from the line of Amar Mourya from Alpha Accurate risers.
So firstly, sir, just to understand more on the demand perspective. As you said that the destocking is the core issue in the export business. So I mean, how long do we see that this destocking issue is going to fade? Is it going to take 2 quarters more, 3 quarter more?
I can give you the information what I understand and more from the industry. If you look at larger global multinational, they also do a very qualitative statement, not a contributor at the time. They say it's a temporary phenomenon and it is already expected soon.
If you read the top 3, 4 multinational companies with market cap more than $100 billion, that's what they say. So it's very difficult to predict the global environment at this point of time. And if I tell you next quarter or 2 quarters, I may be completely wrong because I do not have the information myself. I can only speak for how the industry is moving at this point of time. And at this point of time, we see a sluggishness and we do not see a lot of recovery at this point in time.
I was trying to understand more from the client perspective. A lot of your clients are large global clients and you have a strong relationship from last 5, 7 years. So any color like from a client perspective that this is going to over, let's say, in 1 quarter, 2 quarter. I was trying to understand from the client specific because our share in the global pie is insignificant today.
Correct. Correct. But as I said in my earlier question as well, the percentage of what we have among the global pie at this point is not important because the prospective customers who could be our customers in the future are grappling with their own problems to add another new problem of looking at a new supplier at this point of time. They have their own problems of overstocking and large inventories.
So it would only be opportunity for us to engage with them at times when it would add value. At this point of time, they have to look at their inventory levels, which have been stocked up over the last 1.5, 2, 2.5 years. And that would have -- those inventories before we can engage into something which is alternative supplier of better margins for them, lower prices for them and so on.
And 1 thing to add on that. On year-on-year basis, we are down by 8% to 9%. And in this quarter, we -- our sales had grown, but we have not lost any of the customers.
I mean the demand is more in now or any...
Sorry, Mr. Amar, you are not audible there. Could you please repeat your question?
I'm saying what is the color for the domestic business at this point of time? I mean what is the outlook there?
So the outlook looks sluggish, as I explained earlier, and we do not see any immediate complete recouping at this point of time in the domestic business.
Okay. But then you are confident about the full year growth despite all this outlook. So what is behind that?
Behind that is, as I explained in my earlier question, we see better inflow of orders, fresh orders as compared to last year, but not where we expect it to be, but order flow is much better than what we had last year. Of course, do not have a large pending order book what we had last year in the first few months, but the fresh order inflow is much better.
I mean our kind of Q2, Q3 and Q4 is always better than Q1. So it is very difficult to judge the full year on the basis of Q1.
Okay. Okay. And order book growth on a year-over-year basis would be how much in this quarter?
Approximately 4% to 5%.
Our next question is from the line of Ani Singh from Nuvama.
Sir, 2 questions. I think a couple of things has already been clarified. But still on -- when we see a slowdown in life science industry, despite we see in this quarter most of segment in life science, like pharmaceuticals or even the R&D-based players hospitals, all have shown very good numbers. I think for export markets, there may be some volatility, but at least in India market. Domestic market. The other indicators are showing, most of indicators are showing that there has been a growth.
Also, in Q4, we had a very good number. Destocking is the reason then how come from Q4 to even that we are stocking region cropped up because now it's 1 year more than 1 year, you coded related things as varied. So what is the disconnect or the business model probably I'm not able to understand that how the demand has actually gone down in this quarter?
Sure. So as you said, the hospitals and some of the life science companies must have done very well in Q1 of FY '24 in India. However, the sourcing of these companies for plastic lab there has come down. And all we are related to as a company is how much of plastic collaborate as a particular company buy and what can we contribute to that share? So that sourcing mix of plastic at a fortune of plastic are is down and hence, our numbers are down.
And regarding the destocking and how Q4 was higher and then Q1 is further lower. If you look carefully, our Q4 was also a slight degrowth. I would say almost flattish as compared to Q4 of last year. This will be growth of about INR 1.5 crores, right? So the industry was not in the best place because we did not show a year-on-year quarter growth between Q4 of last year and Q4 before that year, a huge growth. In fact, it was a INR 1.5 crores decline.
So generally, Q4 is a very strong year in India because simply we look to complete their budgets in purchases. Distributors look to complete their targets. People look to complete their target. So it's a large quarter. It's not equally divided between 4 quarters. It's a, I would say, 35% of the business comes in 1 quarter compared to 25% equally divided.
So that's what we experienced and internationally as well as I explained in my last question was that companies have shown a better performance. And then again, the performance has slipped a little bit in Q2, and they have not shown that -- they have not been able to continue the momentum into Q2. And we've been no different because we only have international peers listed for us to look at comparisons with. There is no other domestic listed there.
And if you see our Q1 figure, our domestic revenue, they did it from 48 to 45, and explore lease from 20 to 17. So the growth came mostly from the export market, not from the [indiscernible] market. .
So last year, it was 30%, nearly 30% was the export contribution in FY '23. That has come down to 27%, right? So 3% contribution has come down. So this is a not a big part of business and the overall business, actually, the domestic being a meter part. So that person actually wanted expansion. But any secondly, sir, on the next thing that in Panchla plant earlier that was supposed to come in August 23. Now it so Q4. So are we going to capitalize this plant in this year itself? Or that would be that now go to next year also?
So we capitalize all the machinery and plant in a proportional way, as it would further foot for example, but can loan will be ready by Q3. So once the production will be started, we will capitalize that person only. So -- and the same culture will be capitalized by Q4 or Q1 FY '25 as soon as the portion will be charges.
Basically, that capitalization will not happen in 1 go. As and when the machine will be put to use, that quantity would be capitalized.
And when that machine will be good to use?
So we expect commercial production to start in Q2, beginning of Q3 of this year, and we expect machines to enter in the next few weeks, which is 3 to 4 weeks. But commercial production will take at least 6 to 7 weeks after they enter the facility. So the moment commercial production started to be capitalized.
But you have to capitalize on a fully basis now partially because even if we start production for a small amount, is there any provision that we can do parcel capitalization or because I think this is integrated facility. So I don't know.
We'll have about 25, 30 machines coming, but all 50 will not come together. So 3 will come in capital is free. 6 will come we capitalize. And as and when the numbers will come, we'll capitalize. We've not capitalized for things which have not come before they come and before they start promotional production. So it's not 1 machine making 1 kind of product. It's multiple machines making multiple products. .
Okay. Okay. And how much CapEx we have spent so far and how much is the remaining there?
Sir, out of the total CapEx, we already incurred about [indiscernible].
And some part remains there?
Yes, some parts in India, about [indiscernible] INR 120 crores to INR 150 crores.
So total would be some INR 55 crores, INR 30 crores?
Yes.
Okay. And about Anta plant, what we have stated is there. This is already where we have reached in terms of commercialization or [indiscernible]?
So the construction is on full swing. We expect to receive the nod from the government board for radiation [indiscernible] in the next 4 to 6 weeks. So we expect by before September 30 we receive the license to operate a variation plan, and we expect the facility to be fully completed before the end of the year, which is around December 2023 calendar year.
And post that, we should legally move into. So by the end of December or beginning of January because lately should be put to use in terms of the warehousing and the radiation -- and in terms of the production bid, it would take another 4 to 6 weeks as we are operating out of a rented facility and the movement from the rented facility to be a 4- to 6-week procedure, and that only happen on the facilities fully ready.
[Operator Instructions] Our next question is from the line of Sandip Kumar from [indiscernible] Investor.
Currently you are trading the sale console equipment. So what percentage of it is contributing to the top line?
So at this point of time, we do not know how much would the total top line be as the cell culture product portfolio matures over the next 3 to 4 years. But we expect cell culture business to a full capacity should peak out closer to the INR 100 crores of revenue.
Okay. So how much time it will take to reach that INR 100 crores revenue?
I expect 3 to 4 years after installation of capacity and commercial production.
Okay. Are you taking any steps for ramping up this revenue contribution from sale culture?
So at this point of time, we are initiating marketing activities and making people aware of what we are building and what we are going to be coming out with. But at the end of the day, nobody is convinced unless we feel the product in the hand and actually test the product.
And if the product works well according to their research or according to their production, then only they would be complete to buy from us. So making people aware is 1 thing, But actually, building a product which suits their needs as a number. So only time will say, once we launch our cell culture products as to how well have we -- have our products been accepted by the market by our customers in India and overseas.
Our next question is from the line of Harsh from Marcellus.
Yes. So Rohan, can you just give us an update on the inventory front? Like in March 31, we had around INR 114 crores of inventory. What would that level be right now as long as June 28?
So as of June, our inventory is about INR 112 crores. It includes raw material of [indiscernible], which has been reduced quite significantly compared to the last quarter. Then we are working as a cation we have growth of 45 [indiscernible] we have the travel stock in trade of INR 8.5 crore week and we are taking better INR 6.6 crore billion than other consumer and stores and there are about [indiscernible].
Okay. And in so you reckon that even we have to take any inventory write-offs because of this slowdown in demand because we also have a large inventory, and that inventory hasn't expired as well. So I just wondered if you could on that.
So generally, the inventory for sterile items is about 3 to 5 years depending on the quality of the manufacturing and the sterilization. But the insignificant amount of inventory of ours is sterile. I would say more than 95% of our inventory is nonsterile, which generally holds good for a longer period than 3 to 5 years and can be sold easily.
However, we have very limited inventory, which has been built and there is no demand for it. Most of our inventory has been built based on our manufacturing structure of having to launch new products or having to build large batches of production.
Our next question is from the line of Omkar Kamtekar from Bonanza Portfolio.
Yes. So sir, a follow-up question with respect to raw material costs. Do you see any risk of a raw material cost increase is fair to concern?
Actually, we see raw material prices flattening out to the ones. And in the domestic nonbranded raw material, which is non medical grade, has been quite flat. The international raw material has also seen a very small increase or has been flat, but our purchase prices continue to increase the euro has gone up and the dollar has gone up.
So on an INR absolute term, we see an increase in raw material because of the depreciation of the currency. But on actual prices, raw material, it's very, very flat and under control over the last 4, 5 months.
Okay. Okay. And with respect to the plant, just a clarification, a previous question. So the Panela plant and Amalan, the full commercialization, what was the timeline? I was not able to catch that properly.
So it's 2 separate timelines because the Parts and [indiscernible] plant are apart from each other. They are 2 separate parts various kilometers away from each other. Marsha plant is completely ready. The infrastructure, everything, the clean rooms just not in play. The machines are coming with [indiscernible] and we start selling. So 100%, the plant has been ready for the last 1.5 months, completely ready. And the Amta plant to come in the same position as the Parsha plant, could take approximately another 4 to 5 months by the end of December, we expect.
Okay, okay. And the Pancha plant would be -- what would be the capacity utilization to start. So approximate capacity utilization? So because we can project what's the revenue to be generated for the -- for 1 quarter or the quarter?
So at this point of time, Pancha is going to be a mix of new products as well as capacity expansion. So I would not expect a lot of revenues from capacity expansion if it was to start today because considering the industry trends. But with new products, we would expect revenues coming in. But however, the capacity expansion by the time it comes in the next 3 to 4 months. And if we see a recovery in the industry and growing demand, then it would work in our favor.
Okay. Okay. And what is the fixed asset turnover, so the gross block turnover that you target with respect to the overall CapEx that you actually incur?
Our EBITDA base, we expect our asset on resume on a gross drop should be in the range of 0.65 to 0.7.
So we intend to maintain this going forward or increase again as further as we get. This is for the industry.
We intend to maintain that. [indiscernible] in our table, then it will improve, that it's a good grow [indiscernible].
Okay. So currently, we -- just to understand, the current fixed turnover is 6.7%, and we are wanting to maintain. If the opportunity comes, we can increase?
0.65, not fixed rate.
Okay. 0.65. Got it, got it.
0.65.
[Operator Instructions] Our next question is from the line of Amar Mourya from Alpha Accurate Advisors.
My question is how do you [indiscernible].
May we request you to use your handset, please. You're not audible, sir.
So My question is, how do you expect that and PG products to contribute to your revenue? And how do you expect capacity utilization for those 2 products going forward?
So at peak, based on our capacity that we have put, we expect revenue of approximately INR 35 crores to INR 40 crores at least from the pet and products, and most of these products are used in bioproduction and production lines. So there is a process of validation by customer. It's not a general lab product use search laboratory by biotech or a pharma company, but gives more introduction lines. So we are seeing a strong appreciation and demand for our products as we launch these products over the last 2 to 2.5 months and continue to launch some sizes. So we see a good positive feedback, and we are hopeful on good revenue in the coming quarters from these products.
For the upcoming couple of quarters?
So we started detailing the orders from the customers for [indiscernible] others, and we said that the market share will increase further. But we don't -- we cannot anticipate what will be those numbers.
Apart from this, my second question is for serological pipes, which pipes, which you're going to start. Has that started? And how do you expect that to contribute?
It has started, but not in the same, but where we can anticipate and expand global business. But we, again, no different to the other product line, we got a very positive response from the domestic market, and we have started revenues in small numbers for the sale logics from our pilot production, match production.
Okay. And so my last question is apart from serological pipes and the patent contribution going forward, what do you expect for the base of revenue to grow apart from these 2 streams?
Do you expect from -- considering the industry went back to normalized levels, we expect large revenue to come in from our existing product line as we build strong capacities to be able to take on large projects internationally as well as in India. And cell culture products and bioprocess products, which would be added in Partly and Amar, respectively, along with boosting of our equipment business as we bring in more products on the equipment category. So it would be a 3-year process, 1 new products, 1 in the equipment and on our existing capacity expansions.
Our next question is from the line of Omkar Kamtekar from Bonanza Portfolio.
Sir, with respect to the new products that we are going to introduce from the Planchard, the margin profile for these products would be in line with the current profile? Or are they margin accretive?
No, it will be in line with the current products.
Okay. And with the [indiscernible] facility, we are also having a warehousing there. So are we going to gain benefits with respect to some cost savings and will that add into our margin positively?
We don't expect post, but we expect operational efficiencies because we need a bigger place, to be able to tackle revenues, which are significantly higher than INR 300 crores at our current infrastructure setup. Beyond INR 300 crores, it's slightly difficult to handle. So we need a much more robust and better infrastructure to conduct a global business at a faster pace, in a fastest way.
Okay. Okay. So the [indiscernible] plant will be more of an operational efficiency?
Operational efficiency, at about 80% of the plant area, 5% to 10% would be the Gamma plant and another 10% would be manufacturing. .
Ladies and gentlemen, that was the last question of our question-and-answer session. I would now like to turn the conference over to the management for closing comments.
I take this opportunity to thank everyone for joining the call. We will keep updating the investor community on a regular basis for incremental updates on your company I hope we have been able to address all your queries. For any further information, kindly get in touch with us or Strategic Growth Advisors, our Investor Relations advisers. Thank you once again.
Thank you. On behalf of AMBIT, Capital, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.